Medidata, a global provider of cloud-based solutions for clinical research in life sciences, hsd announced that Boehringer Ingelheim has selected the Medidata Clinical Cloud® to accelerate innovation across all of its drug development programs. The top-20 global pharmaceutical company will leverage Medidata’s technology platform to bring new insights and knowledge into multiple stages of the Boehringer Ingelheim drug development process, enabling its researchers to conduct faster, more accurate and more cost-effective clinical trials.
In supporting more than 10,000 clinical studies, 370,000 investigational sites and more than 2.7 million trial volunteers, the Medidata platform is driving a transformation in clinical trial design and execution, leading to better science and new medical breakthroughs for patients. Leveraging the power of this platform, Boehringer Ingelheim will integrate Medidata’s study planning, data management, data analytics and risk-based monitoring (RBM) capabilities into multiple stages of its drug development process.
“Boehringer Ingelheim creates therapeutic value through continuous innovation, so fortifying our R&D efforts with smart, agile technology is vital to our continued success,” said Klaus Stern, global head of Biostatistics & Data Sciences at Boehringer Ingelheim. “Medidata’s platform of cloud-based solutions and data analytics will increase the efficiency of our R&D and help us be more nimble in developing and conducting increasingly complex clinical trials. Ultimately, this can bring new medicines to patients sooner, which is what our team is working to do every day.”